Pharma R&D productivity is decreasing. The COVID-19 pandemic has meant most pharma companies have rapidly turned towards digital strategies. The […]
According to new research from the University of East Anglia in collaboration with Boots UK and Leiden University, four million […]
The growing epidemic of “The Silent Liver Disease” Non-alcoholic fatty liver disease (NAFLD) is experiencing a meteoric rise globally. NAFLD […]
We summarise a recent pilot study, published as preprint in medRxiv, that explored the practical barriers and facilitators experienced by […]
Front Line Genomics is delighted to announce the launch of D4 Global: the world’s first truly global event focusing on […]
The pharmaceutical industry is undergoing a big change. The industry is going through a big phase due to disruptive technologies. […]
A medication that works for one person may not be as effective for others, or may cause side effects. One […]
The PGx program is an industry-first solution that will protect patients from being prescribed ineffective or harmful drugs.
FLG: Can you introduce yourself and your work? I’m Guillermo del Angel and I’m the Senior Director for Data Science […]
Pharmacogenetics (PGx) is the study of how an individual’s genetic makeup affects their drug response and metabolism. An understanding of PGx could help clinicians make prescribing decisions and has the potential to be implemented in routine care worldwide. PGx has understandably been gaining traction and support, with pharmacogenomic elements being implemented into many international Genomic studies.